NWY-001(Biocytogen Pharmaceuticals)

N/A

Report date: 2024/01/09 15:26:33

Base Information

Drug NameNWY-001(Biocytogen Pharmaceuticals)
Drug Alias NameYH-008NWY-001(Biocytogen Pharmaceuticals)NWY001(Biocytogen Pharmaceuticals)YH008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-PD-1Tumor necrosis factor receptor superfamily member 5 agonistsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsProgrammed cell death protein 1Tumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEucure Pharmaceutical Technology (Beijing) Co LtdBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Microchip Xinyu Biotechnology Co LtdEucure Pharmaceutical Technology (Beijing) Co LtdChipscreen Biosciences Ltd
Inactive CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A